120
Participants
Start Date
July 18, 2024
Primary Completion Date
June 15, 2028
Study Completion Date
June 15, 2030
PEP-CMV
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
Temozolomide
Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
Tetanus Diphtheria Vaccine
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
NOT_YET_RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
Children's National Medical Center, Washington D.C.
RECRUITING
Duke Cancer Center, Durham
RECRUITING
Nicklaus Children's Hospital, Miami
RECRUITING
Nationwide Children's Hospital, Columbus
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
NOT_YET_RECRUITING
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RECRUITING
St. Louis Children's Hospital, St Louis
RECRUITING
Texas Children's Hospital, Houston
RECRUITING
Children's Hospital Colorado, Aurora
RECRUITING
Seattle Children's Hospital, Seattle
NOT_YET_RECRUITING
Dana-Farber Cancer Institute, Boston
Nationwide Children's Hospital
OTHER